La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.

Identifieur interne : 001A33 ( Main/Exploration ); précédent : 001A32; suivant : 001A34

Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.

Auteurs : Renju Kuriakose [Canada] ; A Jon Stoessl

Source :

RBID : pubmed:20887875

English descriptors

Abstract

Radiotracer imaging (RTI) techniques such as positron emission tomography (PET) allow the in vivo assessment of nigrostriatal DA function in Parkinson's disease and have provided valuable insights into the mechanisms of nigrostriatal degeneration and the consequent compensatory changes. Moreover, functional imaging serves as an excellent tool in the assessment of the progression of PD and the evolution of treatment-related complications. However, various studies have shown discordance between clinical progression of PD and nigrostriatal degeneration estimated by PET or SPECT, and no RTI technique can be reliably used as a biomarker for progression of PD. Presynaptic dopaminergic imaging has consistently demonstrated an anterior-posterior gradient of dopaminergic dysfunction predominantly affecting the putamen, with side-to-side asymmetry in tracer binding. Dopaminergic hypofunction in the striatum follows a negative exponential pattern with the fastest rate of decline in early disease. Evaluation of central pharmacokinetics of levodopa action by PET has demonstrated the role of increased synaptic dopamine turnover and downregulation of the dopamine transporter in the pathophysiology of levodopa-induced dyskinesias. In PD with behavioral complications such as impulse control disorders, increased levels of dopamine release have been observed in the ventral striatum during performance of a positive reward task, as well as loss of deactivation in orbitofrontal cortex in response to negative reward prediction errors. This suggests that there is a pathologically heightened "reward" response in the ventral striatum together with loss of the capacity to respond to negative outcomes. Overall, functional imaging with PET is an excellent tool for understanding the disease and its complications; however, caution must be applied in interpretation of the results.

DOI: 10.1016/S0079-6123(10)84009-9
PubMed: 20887875


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.</title>
<author>
<name sortKey="Kuriakose, Renju" sort="Kuriakose, Renju" uniqKey="Kuriakose R" first="Renju" last="Kuriakose">Renju Kuriakose</name>
<affiliation wicri:level="1">
<nlm:affiliation>Pacific Parkinson’s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson’s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20887875</idno>
<idno type="pmid">20887875</idno>
<idno type="doi">10.1016/S0079-6123(10)84009-9</idno>
<idno type="wicri:Area/PubMed/Corpus">000D98</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D98</idno>
<idno type="wicri:Area/PubMed/Curation">000D98</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D98</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D98</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D98</idno>
<idno type="wicri:Area/Ncbi/Merge">000D47</idno>
<idno type="wicri:Area/Ncbi/Curation">000D47</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D47</idno>
<idno type="wicri:Area/Main/Merge">001B41</idno>
<idno type="wicri:Area/Main/Curation">001A33</idno>
<idno type="wicri:Area/Main/Exploration">001A33</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.</title>
<author>
<name sortKey="Kuriakose, Renju" sort="Kuriakose, Renju" uniqKey="Kuriakose R" first="Renju" last="Kuriakose">Renju Kuriakose</name>
<affiliation wicri:level="1">
<nlm:affiliation>Pacific Parkinson’s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson’s Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</analytic>
<series>
<title level="j">Progress in brain research</title>
<idno type="eISSN">1875-7855</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Biomarkers</term>
<term>Cerebrovascular Circulation</term>
<term>Corpus Striatum (diagnostic imaging)</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Disease Progression</term>
<term>Dopamine (physiology)</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Movement Disorders (diagnostic imaging)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (diagnostic imaging)</term>
<term>Positron-Emission Tomography</term>
<term>Radiopharmaceuticals</term>
<term>Substantia Nigra (diagnostic imaging)</term>
<term>Synapses (pathology)</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en">
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Biomarkers</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en">
<term>Corpus Striatum</term>
<term>Movement Disorders</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Synapses</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cerebrovascular Circulation</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Positron-Emission Tomography</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Radiotracer imaging (RTI) techniques such as positron emission tomography (PET) allow the in vivo assessment of nigrostriatal DA function in Parkinson's disease and have provided valuable insights into the mechanisms of nigrostriatal degeneration and the consequent compensatory changes. Moreover, functional imaging serves as an excellent tool in the assessment of the progression of PD and the evolution of treatment-related complications. However, various studies have shown discordance between clinical progression of PD and nigrostriatal degeneration estimated by PET or SPECT, and no RTI technique can be reliably used as a biomarker for progression of PD. Presynaptic dopaminergic imaging has consistently demonstrated an anterior-posterior gradient of dopaminergic dysfunction predominantly affecting the putamen, with side-to-side asymmetry in tracer binding. Dopaminergic hypofunction in the striatum follows a negative exponential pattern with the fastest rate of decline in early disease. Evaluation of central pharmacokinetics of levodopa action by PET has demonstrated the role of increased synaptic dopamine turnover and downregulation of the dopamine transporter in the pathophysiology of levodopa-induced dyskinesias. In PD with behavioral complications such as impulse control disorders, increased levels of dopamine release have been observed in the ventral striatum during performance of a positive reward task, as well as loss of deactivation in orbitofrontal cortex in response to negative reward prediction errors. This suggests that there is a pathologically heightened "reward" response in the ventral striatum together with loss of the capacity to respond to negative outcomes. Overall, functional imaging with PET is an excellent tool for understanding the disease and its complications; however, caution must be applied in interpretation of the results.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Kuriakose, Renju" sort="Kuriakose, Renju" uniqKey="Kuriakose R" first="Renju" last="Kuriakose">Renju Kuriakose</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A33 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A33 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20887875
   |texte=   Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20887875" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022